Altered fecal microbial and metabolic profiles reveal potential mechanisms underlying anemia in patients with chronic renal failure

ABSTRACT:

The gut microbiomes communicate with kidney and may play a crucial role in the development of anemia in patients with chronic renal failure (CRF). However, the alterations in microbiota and their association with functional metabolites remain unclear. We performed metagenomics and untargeted metabolomics in a cohort of 30 patients with anemia of CRF and 20 healthy controls (HCs) to identify the characteristics of the gut microbiome and explore its potential interactions with the host. Decreased microbiota diversity and significant compositional differences were observed in the patients with anemia of CRF. We identified six gut microbiotas significantly changed in patients with anemia of CRF, particularly Faecalibacterium prausnitzii, Prevotella copri and Escherichia coli that were closely correlated with hemoglobin (Hb) levels and estimated glomerular filtration rate. And these changes were accompanied by functional alterations in distinctive microbial pathways. Further fecal and serum metabolomics revealed fecal 12-KETE-LB4 in arachidonic acid metabolism, uracil and L-aspartic acid in beta-alanine metabolism, gulonic acid in ascorbate and aldarate metabolism, accompanied by the top 15 differential serum metabolites were closely correlated with Hb levels. Furthermore, we observed a complex co-occurrence between anemia of CRF-related gut microbiota species and the characterized metabolites. Moreover, a non-invasive model incorporating Faecalibacterium prausnitzii, Prevotella copri, combined with fecal 12-KETE-LB4, uracil, L-aspartic acid and gulonic acid, distinguished patients with anemia of CRF from HCs (area under the curve: 0.879). Collectively, our results suggest that a disordered gut microbiome associated with functional metabolites may be a non-invasive diagnostic and therapeutic target for anemia of CRF.

Linked studies:

UPLC-MS assays of Fecal samples are reported in this study.

UPLC-MS assays of Blood Plasma samples are reported in MTBLS12576.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS6334 | MetaboLights | 2025-06-13

REPOSITORIES: MetaboLights